280 related articles for article (PubMed ID: 25296978)
1. Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.
Wagner V; Hose D; Seckinger A; Weiz L; Meißner T; Rème T; Breitkreutz I; Podar K; Ho AD; Goldschmidt H; Krämer A; Klein B; Raab MS
Oncotarget; 2014 Nov; 5(21):10237-50. PubMed ID: 25296978
[TBL] [Abstract][Full Text] [Related]
2. YM155 induces apoptosis through downregulation of specificity protein 1 and myeloid cell leukemia-1 in human oral cancer cell lines.
Sachita K; Yu HJ; Yun JW; Lee JS; Cho SD
J Oral Pathol Med; 2015 Nov; 44(10):785-91. PubMed ID: 25475012
[TBL] [Abstract][Full Text] [Related]
3. YM155 induces caspase-8 dependent apoptosis through downregulation of survivin and Mcl-1 in human leukemia cells.
Feng W; Yoshida A; Ueda T
Biochem Biophys Res Commun; 2013 May; 435(1):52-7. PubMed ID: 23618862
[TBL] [Abstract][Full Text] [Related]
4. YM155 suppresses cell proliferation and induces cell death in human adult T-cell leukemia/lymphoma cells.
Sasaki R; Ito S; Asahi M; Ishida Y
Leuk Res; 2015 Dec; 39(12):1473-9. PubMed ID: 26547260
[TBL] [Abstract][Full Text] [Related]
5. Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263.
Tang H; Shao H; Yu C; Hou J
Biochem Pharmacol; 2011 Nov; 82(9):1066-72. PubMed ID: 21784061
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS.
Minoda M; Kawamoto T; Ueha T; Kamata E; Morishita M; Harada R; Toda M; Onishi Y; Hara H; Kurosaka M; Akisue T
Int J Oncol; 2015 Sep; 47(3):891-9. PubMed ID: 26166250
[TBL] [Abstract][Full Text] [Related]
7. YM155 induces EGFR suppression in pancreatic cancer cells.
Na YS; Yang SJ; Kim SM; Jung KA; Moon JH; Shin JS; Yoon DH; Hong YS; Ryu MH; Lee JL; Lee JS; Kim TW
PLoS One; 2012; 7(6):e38625. PubMed ID: 22723871
[TBL] [Abstract][Full Text] [Related]
8. Targeting survivin with YM155 (Sepantronium Bromide): a novel therapeutic strategy for paediatric acute myeloid leukaemia.
Smith AM; Little EB; Zivanovic A; Hong P; Liu AK; Burow R; Stinson C; Hallahan AR; Moore AS
Leuk Res; 2015 Apr; 39(4):435-44. PubMed ID: 25659731
[TBL] [Abstract][Full Text] [Related]
9. YM155 sensitizes TRAIL-induced apoptosis through cathepsin S-dependent down-regulation of Mcl-1 and NF-κB-mediated down-regulation of c-FLIP expression in human renal carcinoma Caki cells.
Woo SM; Min KJ; Seo BR; Kwon TK
Oncotarget; 2016 Sep; 7(38):61520-61532. PubMed ID: 27528031
[TBL] [Abstract][Full Text] [Related]
10. Small Molecule Survivin Inhibitor YM155 Displays Potent Activity Against Human Osteosarcoma Cells.
Zhang S; Wang X; Gu Z; Wang L
Cancer Invest; 2016 Sep; 34(8):401-7. PubMed ID: 27559851
[TBL] [Abstract][Full Text] [Related]
11. Combination of YM155, a survivin suppressant with a STAT3 inhibitor: a new strategy to treat diffuse large B-cell lymphoma.
Kaneko N; Kita A; Yamanaka K; Mori M
Leuk Res; 2013 Sep; 37(9):1156-61. PubMed ID: 23746965
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
[TBL] [Abstract][Full Text] [Related]
13. AML sensitivity to YM155 is modulated through AKT and Mcl-1.
de Necochea-Campion R; Diaz Osterman CJ; Hsu HW; Fan J; Mirshahidi S; Wall NR; Chen CS
Cancer Lett; 2015 Sep; 366(1):44-51. PubMed ID: 26118775
[TBL] [Abstract][Full Text] [Related]
14. Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells.
Tao YF; Lu J; Du XJ; Sun LC; Zhao X; Peng L; Cao L; Xiao PF; Pang L; Wu D; Wang N; Feng X; Li YH; Ni J; Wang J; Pan J
BMC Cancer; 2012 Dec; 12():619. PubMed ID: 23267699
[TBL] [Abstract][Full Text] [Related]
15. Targeting of Survivin Pathways by YM155 Inhibits Cell Death and Invasion in Oral Squamous Cell Carcinoma Cells.
Zhang W; Liu Y; Li YF; Yue Y; Yang X; Peng L
Cell Physiol Biochem; 2016; 38(6):2426-37. PubMed ID: 27287458
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
[TBL] [Abstract][Full Text] [Related]
17. Interleukin enhancer-binding factor 3/NF110 is a target of YM155, a suppressant of survivin.
Nakamura N; Yamauchi T; Hiramoto M; Yuri M; Naito M; Takeuchi M; Yamanaka K; Kita A; Nakahara T; Kinoyama I; Matsuhisa A; Kaneko N; Koutoku H; Sasamata M; Yokota H; Kawabata S; Furuichi K
Mol Cell Proteomics; 2012 Jul; 11(7):M111.013243. PubMed ID: 22442257
[TBL] [Abstract][Full Text] [Related]
18. YM155 Reverses Statin Resistance in Renal Cancer by Reducing Expression of Survivin.
Nitta T; Koike H; Miyao T; Miyazawa Y; Kato H; Furuya Y; Sekine Y; Suzuki K
Anticancer Res; 2017 Jan; 37(1):75-80. PubMed ID: 28011476
[TBL] [Abstract][Full Text] [Related]
19. YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context.
Jane EP; Premkumar DR; DiDomenico JD; Hu B; Cheng SY; Pollack IF
Mol Cancer Ther; 2013 Mar; 12(3):326-38. PubMed ID: 23325792
[TBL] [Abstract][Full Text] [Related]
20. YM155 induces apoptosis through proteasome-dependent degradation of MCL-1 in primary effusion lymphoma.
Kojima Y; Hayakawa F; Morishita T; Sugimoto K; Minamikawa Y; Iwase M; Yamamoto H; Hirano D; Imoto N; Shimada K; Okada S; Kiyoi H
Pharmacol Res; 2017 Jun; 120():242-251. PubMed ID: 28396094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
